| Literature DB >> 27869204 |
Li Zhu1,2, Jiaqi Li1,2, Nan Dong1,2, Fanglin Guan1,2, Yufeng Liu3, Dongliang Ma4,5, Eyleen L K Goh4,5,6,7, Teng Chen1,2.
Abstract
Methamphetamine (METH) is a highly addictive psychostimulant that elicits aberrant changes in the expression of microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) in the nucleus accumbens of mice, indicating a potential role of METH in post-transcriptional regulations. To decipher the potential consequences of these post-transcriptional regulations in response to METH, we performed strand-specific RNA sequencing (ssRNA-Seq) to identify alterations in mRNA expression and their alternative splicing in the nucleus accumbens of mice following exposure to METH. METH-mediated changes in mRNAs were analyzed and correlated with previously reported changes in non-coding RNAs (miRNAs and lncRNAs) to determine the potential functions of these mRNA changes observed here and how non-coding RNAs are involved. A total of 2171 mRNAs were differentially expressed in response to METH with functions involved in synaptic plasticity, mitochondrial energy metabolism and immune response. 309 and 589 of these mRNAs are potential targets of miRNAs and lncRNAs respectively. In addition, METH treatment decreases mRNA alternative splicing, and there are 818 METH-specific events not observed in saline-treated mice. Our results suggest that METH-mediated addiction could be attributed by changes in miRNAs and lncRNAs and consequently, changes in mRNA alternative splicing and expression. In conclusion, our study reported a methamphetamine-modified nucleus accumbens transcriptome and provided non-coding RNA-mRNA interaction networks possibly involved in METH addiction.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27869204 PMCID: PMC5116666 DOI: 10.1038/srep36993
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Treatment schedules and overview of the ssRNA-Seq data.
(A) The schematic timeline of METH treatment regimen. Habituation (day (−7)–(−1)): The mice were handled daily for 1 week to adapt to the experimenter before treatment. Pre-test (day 1-2): mice were given once daily injections of saline for two consecutive days. Development (day 3–7): After pre-test, mice were divided into two groups randomly, and were given once daily injections of METH (2 mg/kg) or saline for five consecutive days. Transfer (day 8–9): two groups of mice were experienced two injection-free days. Expression (day 10): mice were given a challenge injection of either 2 mg/kg dose of METH or saline. Horizontal locomotor activity was performed 60 minutes before and after the injections on all drug treatment days. (B) Statistical alignment of the sequencing data from the saline and METH groups. Unique mach represents the mapped reads that aligned to only one position in the mouse genome. Multi-position mach represents the mapped reads that aligned to more than one positions in the mouse genome. Total unmapped indicates reads that did not match to the mouse genome.
Figure 2Expression profiles of mRNAs within each group and correlated interactions formed by METH-induced ncRNAs-mRNAs.
Pearson correlation scatter plot comparing log10RPKM of shared pcGenes that expressed both in saline1 and saline2 samples (A, r = 0.99, P < 0.001) and in METH1 and METH2 samples (B, r = 0.99, P < 0.001) showed nearly equivalent expression profile within the samples of each group. RPKM: The number of uniquely mapped reads per kilobase per million mappable reads. Interaction networks formed by miRNA-mRNAs and lncRNAs-mRNAs were shown by the fold change of miRNAs (C, x-axis) and lncRNAs (D, x-axis) identified in NAc of mice following METH exposure1718 and their potential target genes with significant changes (y-axis) in response to METH (current study).
GO enrichment of DEGs.
| GO term | EF | |
|---|---|---|
| Cellular component | ||
| GO:0015934 large ribosomal subunit | 3.42 | 3.50E-07 |
| GO:0033267 axon part | 3.00 | 1.21E-07 |
| GO:0005840 ribosome | 2.92 | 2.18E-11 |
| GO:0005743 mitochondrial inner membrane | 2.86 | 3.38E-07 |
| GO:0030425 dendrite | 2.86 | 1.25E-07 |
| GO:0030427 site of polarized growth | 2.84 | 1.22E-06 |
| GO:0030136 clathrin-coated vesicle | 2.66 | 2.18E-08 |
| GO:0045202 synapse | 2.65 | 2.40E-06 |
| Molecular function | ||
| GO:0005198 structural molecule activity | 2.19 | 2.25E-11 |
| GO:0019900 kinase binding | 2.00 | 1.30E-05 |
| Biological process | ||
| GO:0019058 viral infectious cycle | 3.79 | 1.48E-16 |
| GO:0001505 regulation of neurotransmitter levels | 3.51 | 4.54E-11 |
| GO:0048167 regulation of synaptic plasticity | 3.51 | 1.53E-06 |
| GO:0022415 viral reproductive process | 3.43 | 3.50E-16 |
| GO:0007268 synaptic transmission | 3.04 | 3.33E-14 |
| GO:0050804 regulation of synaptic transmission | 2.85 | 1.36E-10 |
| GO:0023061 signal release | 2.77 | 9.87E-09 |
| GO:0003001 generation of a signal involved in cell-cell signaling | 2.77 | 9.87E-09 |
| GO:0051969 regulation of transmission of nerve impulse | 2.63 | 1.76E-10 |
| GO:0006887 exocytosis | 2.63 | 1.80E-06 |
| GO:0031644 regulation of neurological system process | 2.57 | 1.06E-10 |
| GO:0015980 energy derivation by oxidation of organic compounds | 2.52 | 2.73E-08 |
| GO:0048667 cell morphogenesis involved in neuron differentiation | 2.44 | 3.57E-06 |
| GO:0006091 generation of precursor metabolites and energy | 2.35 | 9.69E-10 |
| GO:0055114 oxidation-reduction process | 2.28 | 1.46E-08 |
| GO:0007610 behavior | 2.12 | 3.90E-10 |
| GO:0006412 translation | 2.06 | 3.67E-08 |
1indicated enrichment factor.
2P values were calculated via hypergeometric tests and go with a correction.
Full list of miRNAs-DEGs.
| miRNA | Fold change | Up-regulated genes | Down-regulated genes |
|---|---|---|---|
| miR-101a-3p | −1.177 | ||
| miR-101b-3p | −1.096 | ||
| miR-106b-5p | −1.104 | ||
| miR-127-5p | −1.798 | ||
| miR-138-5p | −1.285 | ||
| miR-145a-5p | −1.175 | ||
| miR-153-3p | −2.289 | ||
| miR-204-3p | 1.044 | ||
| miR-212-3p | −1.452 | ||
| miR-218-5p | −1.165 | ||
| miR-299a-3p | −1.056 | ||
| miR-29a-5p | −1.584 | ||
| miR-29b-3p | −2.214 | ||
| miR-29c-3p | −1.634 | ||
| miR-300-3p | −1.228 | ||
| miR-301a-5p | −1.165 | ||
| miR-3068-5p | −1.522 | ||
| miR-30e-5p | −2.002 | ||
| miR-324-5p | −1.133 | ||
| miR-33-5p | −3.198 | ||
| miR-338-3p | −1.226 | ||
| miR-341-3p | −2.215 | ||
| miR-345-5p | −1.149 | ||
| miR-34c-5p | −1.026 | ||
| miR-378c | −1.822 | ||
| miR-434-5p | −1.394 | ||
| miR-503-5p | −1.622 | ||
| miR-551b-3p | −2.332 | ||
| miR-708-3p | −1.471 | ||
| miR-873a-5p | −1.867 | ||
| miR-99b-3p | −1.070 | ||
| miR-486-3p | −1.282 | ||
| miR-764-3p | −1.275 |
KEGG pathway enrichment of DEGs for miRNAs and lncRNAs.
| Pathways | miRNAs-DEGs | lncRNAs-DEGs | ||||
|---|---|---|---|---|---|---|
| EF | DEmiRs | EF | DElncRs | |||
| Nicotine addiction | 6.59 | 2.06E-06 | 522 | |||
| Long-term potentiation | 6.40 | 2.98E-12 | 869 | |||
| Cocaine addiction | 3.58 | 2.56E-02 | 3 | |||
| Amphetamine addiction | 3.20 | 2.16E-03 | 7 | 4.61 | 6.47E-08 | 772 |
| Glutamatergic synapse | 2.68 | 4.44E-03 | 5 | 4.75 | 2.20E-10 | 980 |
| Retrograde endocannabinoid signaling | 4.61 | 6.47E-08 | 745 | |||
| Endocrine and other factor-regulated calcium reabsorption | 3.84 | 2.63E-04 | 431 | |||
| Morphine addiction | 2.61 | 1.22E-02 | 7 | 3.14 | 7.61E-04 | 543 |
| GnRH signaling pathway | 2.44 | 1.23E-02 | 4 | |||
| Long-term depression | 2.34 | 4.43E-02 | 4 | 3.70 | 1.85E-04 | 449 |
| Dopaminergic synapse | 2.20 | 1.65E-02 | 5 | 4.35 | 2.88E-10 | 946 |
| Calcium signaling pathway | 3.39 | 1.04E-07 | 1083 | |||
| GABAergic synapse | 3.01 | 1.09E-03 | 561 | |||
| Synaptic vesicle cycle | 2.99 | 1.17E-03 | 494 | |||
| Cholinergic synapse | 2.98 | 4.43E-04 | 603 | |||
| MAPK signaling pathway | 2.07 | 2.40E-03 | 9 | 2.32 | 2.41E-05 | 1119 |
| Neurotrophin signaling pathway | 2.27 | 1.48E-03 | 692 | |||
| Alzheimer’s disease | 2.09 | 5.92E-03 | 603 | |||
| Axon guidance | 2.08 | 2.19E-03 | 861 | |||
| Regulation of actin cytoskeleton | 2.04 | 1.17E-04 | 1225 | |||
| ErbB signaling pathway | 3.46 | 2.94E-05 | 678 | |||
| Insulin signaling pathway | 2.89 | 1.41E-05 | 783 | |||
| Phosphatidylinositol signaling system | 2.67 | 1.86E-03 | 537 | |||
| Wnt signaling pathway | 2.34 | 1.07E-03 | 728 | |||
| VEGF signaling pathway | 2.19 | 2.26E-02 | 425 | |||
| Adherens junction | 2.76 | 9.02E-04 | 541 | |||
| Focal adhesion | 2.21 | 8.30E-05 | 1034 | |||
| Gap junction | 2.19 | 3.03E-02 | 377 | |||
| Type II diabetes mellitus | 3.67 | 3.85E-04 | 460 | |||
| Ubiquitin mediated proteolysis | 2.24 | 2.32E-03 | 661 | |||
| Fatty acid elongation | 9.31 | 4.07E-05 | 2 | |||
| Cysteine and methionine metabolism | 3.74 | 1.10E-02 | 5 | |||
| Oxidative phosphorylation | 3.06 | 4.83E-03 | 5 | |||
| Biosynthesis of secondary metabolites | 2.24 | 9.44E-04 | 10 | |||
| Arginine and proline metabolism | 3.41 | 8.57E-03 | 4 | |||
| Vibrio cholerae infection | 3.03 | 3.11E-03 | 4 | 2.59 | 8.01E-03 | 459 |
| mTOR signaling pathway | 2.73 | 2.35E-02 | 3 | 3.63 | 4.22E-04 | 554 |
| T cell receptor signaling pathway | 2.27 | 7.06E-03 | 580 | |||
| B cell receptor signaling pathway | 2.20 | 1.62E-02 | 429 | |||
| Protein export | 9.09 | 2.05E-04 | 3 | |||
| Ribosome | 3.15 | 1.40E-03 | 4 | |||
| Spliceosome | 2.43 | 4.25E-03 | 3 | |||
1Indicated enrichment factor.
2P values were calculated via hypergeometric tests and go with a correction.
3Indicated number of differentially expressed miRNAs17.
4Indicated number of differentially expressed lncRNAs18.
Figure 3Predicted signaling pathways regulated by differentially expressed miRNAs and lncRNAs in response to METH.
Pathway analysis of DEGs that were putative target genes of differentially expressed miRNA and lncRNAs was carried out to assess their putative biological functions (Table 2). As examples, amphetamine addiction pathway composed of DEGs and their corresponding miRNAs and lncRNAs was shown. Genes with red font suggested an up-regulation while genes with blue font indicated a down-regulation in response to METH.
Figure 4Variations on alternative splicing for genes transcription.
The ASEs types including exon skipping, intron retention, and alternative 5′and3′splicing sites (A5′SS and A3′SS) were analysed. The number of evens showing exon skipping (A), intron retention (B), A5′SS (C) and A3′SS (D) in saline and METH groups of mice were shown respectively. (E) Number of group-specific alternative splicing events. The number of genes corresponding to group-specific alternative splicing events was shown in y-axis.
Figure 5Confirmatory qPCR of DEGs selected from ssRNA-Seq analysis.
Left panels exhibited changes in RPKM detected by ssRNA-Seq. The number above the bars indicated fold change. Right panel depicted changes identified through qPCR. The expression levels were calculated relative to Gapdh. Values are presented as the means ± SEM. Independent-samples t-test, *P < 0.05.Pearsoncorrelation scatter plot comparing the fold change for all selected genes in the NAc as analysed from ssRNA-Seq data (x-axis) and qPCR data (y-axis) was shown in F. R represents the Pearson’s coefficient.